Jubilant Pharmova Share Price

Newspaper Publications

• BSE India
• 2 days 22 hours ago

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Jubilant Pharmova announced Q1FY27 results</strong></span></h3> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427="">The company reported Revenue from Operations of Rs 22,294 million in Q1FY27, reflecting a growth of 17.29% YoY compared to Rs 19,007 million in Q1FY26, and a decline of 2.65% QoQ from Rs 22,900 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Total Income for Q1FY27 stood at Rs 22,493 million, an increase of 17.60% YoY from Rs 19,127 million in Q1FY26, while recording a QoQ decrease of 2.78% from Rs 23,137 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Profit Before Tax reached Rs 864 million in Q1FY27, a decline of 44.04% YoY compared to Rs 1,544 million in Q1FY26, and a QoQ drop of 50.91% from Rs 1,760 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Net Profit for the period was reported at Rs 564 million in Q1FY27, down 44.98% YoY from Rs 1,025 million in Q1FY26, and down 52.72% QoQ from Rs 1,193 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">The Basic Earnings Per Share (EPS) for Q1FY27 was Rs 3.57, compared to Rs 6.49 in Q1FY26 and Rs 7.55 in Q4FY26.</li> </ul> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Standalone Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427="">Revenue from Operations for Q1FY27 was Rs 671 million, representing a YoY increase of 12.77% from Rs 595 million in Q1FY26 and a QoQ decline of 4.55% from Rs 703 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Total Income for the quarter stood at Rs 672 million, showing a growth of 11.63% YoY from Rs 602 million in Q1FY26 and a QoQ decline of 5.08% from Rs 708 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Profit Before Tax reached Rs 98 million in Q1FY27, reflecting a YoY growth of 50.77% compared to Rs 65 million in Q1FY26 and a QoQ growth of 139.02% from Rs 41 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Profit for the period from continuing operations was Rs 73 million in Q1FY27, compared to Rs 41 million in Q1FY26 and Rs 572 million in Q4FY26 (which included a substantial deferred tax credit).</li> <li _ngcontent-ng-c1940132427="">Total Comprehensive Income for Q1FY27 was Rs 74 million, up 29.82% YoY from Rs 57 million in Q1FY26, but down 87.04% QoQ from Rs 571 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Basic EPS for continuing operations stood at Rs 0.46 in Q1FY27, against Rs 0.26 in Q1FY26 and Rs 3.59 in Q4FY26.</li> </ul> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Radiopharma:</strong> This segment reported revenue of Rs 10,221 million in Q1FY27, showing a YoY growth of 17.67% from Rs 8,686 million in Q1FY26. Segment results (profit before tax and interest) stood at Rs 780 million.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Allergy Immunotherapy:</strong> Recorded revenue of Rs 2,144 million in Q1FY27, compared to Rs 1,914 million in Q1FY26. Segment results were Rs 635 million for the quarter.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">CDMO - Sterile Injectables:</strong> Segment revenue grew to Rs 5,198 million in Q1FY27 from Rs 3,926 million in Q1FY26. Segment results were Rs 73 million.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">CRDMO:</strong> Revenue for this segment reached Rs 3,258 million in Q1FY27, up from Rs 3,114 million in Q1FY26. Segment results stood at Rs 356 million.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Generics:</strong> This segment reported revenue of Rs 1,734 million in Q1FY27, compared to Rs 1,660 million in Q1FY26. The segment recorded a loss of Rs 101 million for the quarter.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Proprietary Novel Drugs:</strong> This segment reported a loss of Rs 76 million for Q1FY27.</li> <li _ngcontent-ng-c1940132427="">The company appointed Mr. Prasanth Puliakottu as Senior General Manager - ITS, Head of Information Technology Services and Mr. Santhosh Mathew as Senior General Manager - HRS, Head of Human Resources & Services as Senior Management Personnel effective August 11, 2026.</li> </ul> <p><strong>Shyam S Bhartia, Chairman & Hari S Bhartia, Co-Chairman & Non-Executive Director, Jubilant Pharmova, said</strong>: “We are pleased to announce revenue of Rs 2,229 crore for Q1FY27, which reflects a solid growth of 17% on YoY basis. Revenue growth is broad based across all our business segments, but particularly strong in CDMO Sterile Injectables on the back of technology transfer revenues from the new & third line. EBITDA for the quarter stands at Rs 268 crore. EBITDA margins declined year-on-year, primarily due to the unavailability of high-margin SPECT radiopharmaceutical products in the Radiopharmaceuticals business. Additionally, margins were impacted by negligible third-party revenues and higher operating expenses, including incremental remediation costs at the CMO Montreal facility. Reported PAT for the period stands at Rs 56 crore. PAT margins decreased due to lower operating profitability and an increase in depreciation.</p> <p>During Q1FY27, post successful media-fills, Commercial batch production for SPECT radiopharmaceuticals has started and these batches are expected to be released in Q2FY27. By H2FY27, all the SPECT Radiopharmaceutical products are expected to be available. Therefore, we anticipate EBITDA margins to start to expand from H2’FY27 onwards.</p> <p>During Q1FY27, we saw continued growth momentum in the Ruby-Fill® installs. In the Allergy Immunotherapy business, we witnessed an increase in demand from both markets, US and Outside US. In the CDMO Sterile Injectables business, we saw incremental revenues from technology transfer programs at Line 3 in Spokane. In the CRDMO business, we are witnessing an increase in revenues from the Biotech customer segment and custom manufacturing. In the Generics Business, we launched two new products. Lastly, in our Proprietary Novel drugs business, we continue to make progress in JBI-802 and JBI-778 clinical trials.”</p> <p><a class="lb" href="/get-document/post/pdf/5778370/" target="_blank">Result PDF</a></p>

• Trendlyne
• 3 days 3 hours ago

Jubilant Pharmova shares fell after Q1 profit plunged 45% YoY to Rs 56 crore, despite revenue rising 17% to Rs 2,229 crore. The profit decline was attributed to weaker operating profitability and higher depreciation, while strong growth across segments, led by CDMO Sterile Injectables, boosted revenue.

• Economic Times
• 3 days 5 hours ago